A randomized, double-bind, placebo-controlled, parallel trial revealed that additional oral arginine supplementation in patients with COVID-19 led to significantly reduced levels of pro-inflammatory IL-2, IL-6, and IFN-γ (Fiorentino et al. 2021). This evidence concerns the gene IL2 and COVID-19.